Targeting Potential of Nanocarriers for Efficient Treatment of H. Pylori Infection
- Authors: Sunil K. Jain1, Kuldeep Rajpoot2, K. Kesavan3, Awesh Yadav4, Umesh Gupta5, Prem N. Gupta6
-
View Affiliations Hide AffiliationsAffiliations: 1 Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India 2 Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India 3 Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India 4 Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India 5 Department of Pharmacy, Central University of Rajasthan, Ajmer, Rajasthan 305801, India 6 CSIR Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India
- Source: Nanoparticles and Nanocarriers Based Pharmaceutical Preparations , pp 157-174
- Publication Date: December 2022
- Language: English
Targeting Potential of Nanocarriers for Efficient Treatment of H. Pylori Infection, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815049787/chap5-1.gif
Helicobacter pylori (H. pylori), a prevalent human-specific pathogen, plays a key role in the development of peptic ulcer disease, gastric carcinoma, and gastric mucosa associated lymphoid tissue lymphoma. Once infected, those bacteria reside below the gastric mucosa adherent to the gastric epithelium, and entry of drugs to this target site is very difficult. The bacteria can also acquire resistance to commonly used antimicrobial drugs. Thus, an effective antimicrobial concentration cannot be achieved in the gastric mucous layer or on the epithelial cell surfaces where H. pylori exist and caused inefficient treatment. Such challenges have encouraged researchers into developing some therapies based on nanotechnology. nbsp;
-
From This Site
/content/books/9789815049787.chap5dcterms_subject,pub_keyword-contentType:Journal105
